PLAT and schizophrenia: In future studies, we should measure the serum tPA-BDNF pathway protein levels in large drug-naïve and well-matched samples and add a post-treatment study, we should further test the differential power of this combination in patulous types of illness, including the anxiety spectrum disorders, different types of schizophrenia and other psychiatric disorders.